Regulatory T-cell recovery in recipients of haploidentical nonmyeloablative hematopoietic cell transplantation with a humanized anti-CD2 mAb, MEDI-507, with or without fludarabine

Experimental Hematology

Volumn 35, Issue 7, 2007, Pages 1140-1152

  Shaffer, Juanita ^a   Villard, Jean ^a   Means, Terry K ^a   Alexander, Stephen ^a   Dombkowski, David ^a   Dey, Bimalangshu R ^a   McAfee, Steven ^a   Ballen, Karen K ^a   Saidman, Susan ^a   Preffer, Frederic I ^a   Sachs, David H ^a   Spitzer, Thomas R ^a   Sykes, Megan ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; FLUDARABINE; INTERLEUKIN 2 RECEPTOR ALPHA; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD2; SIPLIZUMAB; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG;

ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHIMERA; CLINICAL ARTICLE; COHORT ANALYSIS; DRUG DOSE REDUCTION; DRUG EFFECT; EVALUATION; GRAFT REJECTION; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNOLOGICAL TOLERANCE; IRRADIATION; MEMORY T LYMPHOCYTE; MULTIPLE CYCLE TREATMENT; NONMYELOABLATIVE STEM CELL TRANSPLANTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, CD2; ANTIGENS, DIFFERENTIATION; FORKHEAD TRANSCRIPTION FACTORS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY TESTING; HUMANS; INTERFERON TYPE II; T-LYMPHOCYTES, REGULATORY; TRANSFORMING GROWTH FACTOR BETA; TRANSPLANTATION CHIMERA; VIDARABINE;

EID: 34250317456     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exphem.2007.03.018     Document Type: Article

References (63)

1. Sharabi Y., and Sachs D.H. Mixed chimerism and permanent specific transplantation tolerance induced by a non-lethal preparative regimen. J Exp Med 169 (1989) 493-502
2. Pelot M.R., Pearson D.A., Swenson K., et al. Lymphohematopoietic graft-vs-host reactions can be induced without graft-vs-host disease in murine mixed chimeras established with a cyclophosphamide-based non-myeloablative conditioning regimen. Biol Blood Marrow Transplant 5 (1999) 133-143
3. Mapara M.Y., Pelot M., Zhao G., Swenson K., Pearson D., and Sykes M. Induction of stable long-term mixed hematopoietic chimerism following nonmyeloablative conditioning with T cell-depleting antibodies, cyclophosphamide, and thymic irradiation leads to donor-specific in vitro and in vivo tolerance. Biol Blood Marrow Transplant 7 (2001) 646-655
4. Mapara M.Y., Kim Y.-M., Wang S.-P., Bronson R., Sachs D.H., and Sykes M. Donor lymphocyte infusions mediate superior graft-versus-leukemia effects in mixed compared to fully allogeneic chimeras: a critical role for host antigen-presenting cells. Blood 100 (2002) 1903-1909
5. Sykes M., Preffer F., McAffee S., et al. Mixed lymphohematopoietic chimerism and graft-vs-lymphoma effects are achievable in adult humans following non-myeloablative therapy and HLA-mismatched donor bone marrow transplantation. Lancet 353 (1999) 1755-1759
6. Spitzer T.R., MCafee S., Sackstein R., et al. The intentional induction of mixed chimerism and achievement of anti-tumor responses following non-myeloablative conditioning therapy and HLA-matched and mismatched donor bone marrow transplantation for refractory hematologic malignancies. Biol Blood Marrow Transplant 6 (2000) 309-320
7. Anasetti C., Amos D., Beatty P.G., et al. Effect of HLA compatibility on engraftment of bone marrow transplants in patients with leukemia or lymphoma. N Engl J Med 320 (1989) 197-204
8. Martelli M.F., Aversa F., Bachar-Lustig E., et al. Transplants across human leukocyte antigen barriers. Semin Hematol 39 (2002) 48-56
9. Spitzer T.R., MCafee S., Dey B.R., et al. Non-myeloablative haploidentical stem cell transplantation using anti-CD2 monoclonal antibody (MEDI-507)-based conditioning for refractory hematologic malignancies. Transplantation 75 (2003) 1748-1751
10. Henslee-Downey P.J. Mismatched bone marrow transplantation. Curr Opin Oncol 2 (1995) 115-121
11. Butturini A., and Gale R.P. The role of T-cells in preventing relapse in chronic myelogenous leukemia. Bone Marrow Transplant 2 (1987) 351-354
12. Horowitz M.M., Gale R.P., Sondel P.M., et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 75 (1990) 555-562
13. Aversa F., Tabilio A., Velardi A., et al. Treatment of high-risk acute leukemia with T cell-depleted stem cells from related donors with one fully mismatched haplotype. N Engl J Med 339 (1998) 1186-1193
14. Chakraverty R., Cote D., Buchli J., et al. An inflammatory checkpoint regulates recruitment of graft-versus-host reactive T cells to peripheral tissues. J Exp Med 203 (2006) 2021-2031
15. Mapara M.Y., Kim Y.-M., Marx J., and Sykes M. DLI-mediated GVL effects in mixed chimeras established with a non-myeloablative conditioning regimen: extinction of GVL effects coincides with loss of alloreactive cells following conversion to full donor chimerism. Transplantation 76 (2003) 297-305
16. Kraus A.B., Shaffer J., Toh H.C., et al. Early host CD8 T-cell recovery and sensitized anti-donor IL-2-producing and cytolytic T-cell responses associated with marrow graft rejection following nonmyeloablative bone marrow transplantation. Exp Hematol 31 (2003) 609-621
17. Fontenot J.D., Gavin M.A., and Rudensky A.Y. Foxp3 programs the development and function of CD4(+)CD25(+) regulatory T cells. Nat Immunol 4 (2003) 330-336
18. Hori S., Nomura T., and Sakaguchi S. Control of regulatory T cell development by the transcription factor foxp3. Science 299 (2003) 1057-1061
19. Khattri R., Cox T., Yasayko S.A., and Ramsdell F. An essential role for Scurfin in CD4(+)CD25(+) T regulatory cells. Nat Immunol 4 (2003) 337-342
20. Bennett C.L., Christie J., Ramsdell F., et al. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet 27 (2001) 20-21
21. Yagi H., Nomura T., Nakamura K., et al. Crucial role of FOXP3 in the development and function of human CD25+CD4+ regulatory T cells. Int Immunol 16 (2004) 1643-1656
22. Walker M.R., Kasprowicz D.J., Gersuk V.H., et al. Induction of FoxP3 and acquisition of T regulatory activity by stimulated human CD4+. J Clin Invest 112 (2003) 1437-1443
23. Sakaguchi S. Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 22 (2004) 531-562
24. Paust S., Lu L., McCarty N., and Cantor H. Engagement of B7 on effector T cells by regulatory T cells prevents autoimmune disease. Proc Natl Acad Sci U S A 101 (2004) 10398-10403
25. Marie J.C., Letterio J.J., Gavin M., and Rudensky A.Y. TGF-{beta}1 maintains suppressor function and Foxp3 expression in CD4+CD25+ regulatory T cells. J Exp Med 201 (2005) 1061-1067
26. Asseman C., Mauze S., Leach M.W., Coffman R.L., and Powrie F. An essential role for interleukin 10 in the function of regulatory T cells that inhibit intestinal inflammation. J Exp Med 190 (1999) 995-1003
27. Abbas A.K., Murphy K.M., and Sher A. Functional diversity of helper T lymphocytes. Nature 383 (1996) 787-793
28. Pietryga D.W., Blazar B.R., Soderling C.C.B., and Vallera D.A. The effect of T subset depletion on the incidence of lethal graft-versus-host disease in a murine major-histocompatibility-mismatched transplantation system. Transplantation 43 (1987) 442-445
29. Ahmad M., Lecron J.C., Descombe J.J., Tanzer J., and Goube de Laforest P. Endogenous production of prothymocyte differentiating activity by phytohemagglutinin-stimulated T-cell-depleted human marrow. Cell Immunol 103 (1986) 299-310
30. Sullivan K.E., Cutilli J., Piliero L.M., et al. Measurement of cytokine secretion, intracellular protein expression, and mRNA in resting and stimulated peripheral blood mononuclear cells. Clin Diagn Lab Immunol 7 (2000) 920-924
31. Rizzieri D.A., Long G.D., Vredenburgh J.J., et al. Chimerism mediated immunotherapy using Campath T-cell depleted peripheral blood progenitor cells (PBSC) with nonmyeloablative therapy provides reliable, durable allogeneic engraftment. Blood 96 (2000) 521a
32. Kottaridis P.D., Milligan D.W., Chopra R., et al. In vivo CAMPATH-1H prevents GvHD following nonmyeloablative stem-cell transplantation. Cytotherapy 3 (2001) 197-201
33. O'Donnell P.V., Luznik L., Jones R.J., et al. Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide. Biol Blood Marrow Transplant 8 (2002) 377-386
34. Shimazaki C., Fuchida S., Ochiai N., et al. Non-T-cell-depleted HLA-haploidentical stem cell transplantation after reduced-intensity conditioning in advanced haematological malignancies based on feto-maternal microchimerism. Br J Haematol 127 (2004) 474-475
35. Shimazaki C., Ochiai N., Uchida R., et al. Non-T-cell-depleted HLA haploidentical stem cell transplantation in advanced hematologic malignancies based on the feto-maternal michrochimerism. Blood 101 (2003) 3334-3336
36. Tamaki H., Ikegame K., Kawakami M., et al. Successful engraftment of HLA-haploidentical related transplants using nonmyeloablative conditioning with fludarabine, busulfan and anti-T-lymphocyte globulin. Leukemia 17 (2003) 2052-2054
37. Ichinohe T., Uchiyama T., Shimazaki C., et al. Feasibility of HLA-haploidentical hematopoietic stem cell transplantation between noninherited maternal antigen (NIMA)-mismatched family members linked with long-term fetomaternal microchimerism. Blood 104 (2004) 3821-3828
38. Kronenberg M., and Rudensky A. Regulation of immunity by self-reactive T cells. Nature 435 (2005) 598-604
39. Sakaguchi S. Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat Immunol 6 (2005) 345-352
40. Maszyna F., Hoff H., Kunkel D., Radbruch A., and Brunner-Weinzierl M.C. Diversity of clonal T cell proliferation is mediated by differential expression of CD152 (CTLA-4) on the cell surface of activated individual T lymphocytes. J Immunol 171 (2003) 3459-3466
41. Zhan Y., Funda D.P., Every A.L., et al. TCR-mediated activation promotes GITR upregulation in T cells and resistance to glucocorticoid-induced death. Int Immunol 16 (2004) 1315-1321
42. Beyer M., Kochanek M., Darabi K., et al. Reduced frequencies and suppressive function of CD4+ CD25high regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine. Blood 106 (2005) 2018-2025
43. Sorror M.L., Maris M.B., Storer B., et al. Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplantation comorbidities. Blood 104 (2004) 961-968
44. Lopez M., Clarkson M.R., Albin M., Sayegh M.H., and Najafian N. A novel mechanism of action for anti-thymocyte globulin: induction of CD4+CD25+Foxp3+ regulatory T cells. J Am Soc Nephrol 17 (2006) 2844-2853
45. Fudaba Y., Spitzer T.R., Shaffer J., et al. Myeloma responses and tolerance following combined kidney and nonmyeloablative marrow transplantation: in vivo and in vitro analyses. Am J Transplant 6 (2006) 2121-2133
46. Cohen J.L., Trenado A., Vasey D., Klatzmann D., and Salomon B.L. CD4(+)CD25(+) immunoregulatory T Cells: new therapeutics for graft-versus-host disease. J Exp Med 196 (2002) 401-406
47. Taylor P.A., Lees C.J., and Blazar B.R. The infusion of ex vivo activated and expanded CD4(+)CD25(+) immune regulatory cells inhibits graft-versus-host disease lethality. Blood 99 (2002) 3493-3499
48. Blazar B.R., Lees C.J., Martin P.J., et al. Host T cells resist graft-versus-host disease mediated by donor leukocyte infusions. J Immunol 165 (2000) 4901-4909
49. Gonzalez M., Quezada S.A., Blazar B.R., Panoskaltsis-Mortari A., Rudensky A.Y., and Noelle R.J. The balance between donor T cell anergy and suppression versus lethal graft-versus-host disease is determined by host conditioning. J Immunol 169 (2002) 5581-5589
50. Johnson B.D., Konkol M.C., and Truitt R.L. CD25+ immunoregulatory T-cells of donor origin suppress alloreactivity after BMT. Biol Blood Marrow Transplant 8 (2002) 525-535
51. Xia G., Truitt R.L., and Johnson B.D. Graft-versus-leukemia and graft-versus-host reactions after donor lymphocyte infusion are initiated by host-type antigen-presenting cells and regulated by regulatory T cells in early and long-term chimeras. Biol Blood Marrow Transplant 12 (2006) 397-407
52. Edinger M., Hoffmann P., Ermann J., et al. CD4(+)CD25(+) regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat Med 9 (2003) 1144-1150
53. Hanash A.M., and Levy R.B. Donor CD4+CD25+ T cells promote engraftment and tolerance following MHC-mismatched hematopoietic cell transplantation. Blood 105 (2005) 1828-1836
54. Miura Y., Thoburn C.J., Bright E.C., et al. Association of Foxp3 regulatory gene expression with graft-versus-host disease. Blood 104 (2004) 2187-2193
55. Zorn E., Kim H.T., Lee S.J., et al. Reduced frequency of FOXP3+ CD4+CD25+ regulatory T cells in patients with chronic graft-versus-host disease. Blood 106 (2005) 2903-2911
56. de Kleer I., Vastert B., Klein M., et al. Autologous stem cell transplantation for autoimmunity induces immunologic self-tolerance by reprogramming autoreactive T cells and restoring the CD4+CD25+ immune regulatory network. Blood 107 (2006) 1696-1702
57. Gallardo D., Brunet S., Torres A., et al. HLA-DPB1 mismatch in HLA-A-B-DRB1 identical sibling donor stem cell transplantation and acute graft-versus-host disease. Transplantation 77 (2004) 1107-1110
58. Flomenberg N., Baxter-Lowe L.A., Confer D., et al. Impact of HLA class I and class II high-resolution matching on outcomes of unrelated donor bone marrow transplantation: HLA-C mismatching is associated with a strong adverse effect on transplantation outcome. Blood 104 (2004) 1923-1930
59. Petersdorf E.W., Smith A.G., Mickelson E.M., et al. The role of HLA-DPB1 disparity in the development of acute graft-versus-host disease following unrelated donor marrow transplantation. Blood 81 (1993) 1923-1932
60. Zino E., Frumento G., Marktel S., et al. A T-cell epitope encoded by a subset of HLA-DPB1 alleles determines nonpermissive mismatches for hematologic stem cell transplantation. Blood 103 (2004) 1417-1424
61. Fleischhauer K., Locatelli F., Zecca M., et al. Graft rejection after unrelated donor hematopoietic stem cell transplantation for thalassemia is associated with nonpermissive HLA-DPB1 disparity in host-versus-graft direction. Blood 107 (2006) 2984-2992
62. Khan A., Tomita Y., and Sykes M. Thymic dependence of loss of tolerance in mixed allogeneic bone marrow chimeras after depletion of donor antigen. Peripheral mechanisms do not contribute to maintenance of tolerance. Transplantation 62 (1996) 380-387
63. Tomita Y., Sachs D.H., and Sykes M. Myelosuppressive conditioning is required to achieve engraftment of pluripotent stem cells contained in moderate doses of syngeneic bone marrow. Blood 83 (1994) 939-948